J
Jean Pierre Droz
Researcher at Institut Gustave Roussy
Publications - 42
Citations - 5033
Jean Pierre Droz is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Cancer & Chemotherapy. The author has an hindex of 27, co-authored 42 publications receiving 4661 citations. Previous affiliations of Jean Pierre Droz include Lyon College & Claude Bernard University Lyon 1.
Papers
More filters
Journal ArticleDOI
Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG).
Martine Extermann,Matti Aapro,Roberto Bernabei,Harvey J. Cohen,Jean Pierre Droz,Stuart M. Lichtman,Vincent Mor,Silvio Monfardini,Lazzaro Repetto,Liv Wergeland Sørbye,Eva Topinkova +10 more
TL;DR: A CGA, with or without screening, and with follow-up, should be used in older cancer patients, in order to detect unaddressed problems, improve their functional status, and possibly their survival.
Journal ArticleDOI
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
Susanne Krege,Jörg Beyer,Rainer Souchon,Peter Albers,Walter Albrecht,Ferran Algaba,Michael Bamberg,István Bodrogi,Carsten Bokemeyer,Eva Cavallin-Ståhl,Johannes Classen,C Clemm,Gabriella Cohn-Cedermark,Stéphane Culine,Gedske Daugaard,Pieter H.M. De Mulder,Maria De Santis,Maike de Wit,Ronald de Wit,H. G. Derigs,Klaus Peter Dieckmann,Annette Dieing,Jean Pierre Droz,Martin Fenner,Karim Fizazi,Aude Flechon,Sophie D. Fosså,Xavier Garcia del Muro,Thomas Gauler,Lajos Géczi,Arthur Gerl,Jose Ramon Germa-Lluch,Silke Gillessen,Jörg T. Hartmann,Michael Hartmann,Axel Heidenreich,Wolfgang Hoeltl,Alan Horwich,Robert Huddart,Michael Jewett,Johnathan Joffe,William G. Jones,László Kisbenedek,Olbjørn Klepp,S. Kliesch,Kai Uwe Koehrmann,Christian K. Kollmannsberger,Markus A. Kuczyk,Pilar Laguna,Oscar Leiva Galvis,Volker Loy,Malcolm David Mason,Graham M. Mead,Rolf Mueller,Craig R. Nichols,Nicola Nicolai,Tim Oliver,D. Ondruš,Gosse O N Oosterhof,Luis Paz Ares,Giorgio Pizzocaro,Jörg Pont,Tobias Pottek,Thomas Powles,Oliver Rick,Giovanni Rosti,Roberto Salvioni,Jutta Scheiderbauer,Hans U. Schmelz,Heinz Schmidberger,Hans-Joachim Schmoll,Mark Schrader,Felix Sedlmayer,Niels E. Skakkebæk,Aslam Sohaib,Sergei Tjulandin,Padraig Warde,Stefan Weinknecht,Lothar Weissbach,Christian Wittekind,Eva Winter,Lori Wood,Hans von der Maase +82 more
TL;DR: F refinements in the treatment of early- and advanced-stage testicular cancer have emerged from clinical trials, and expert clinical skills will continue to be one of the major determinants for the prognosis of patients with germ cell cancer.
Journal ArticleDOI
Motesanib diphosphate in progressive differentiated thyroid cancer.
Steven I. Sherman,Lori J. Wirth,Jean Pierre Droz,Michael Hofmann,Lars Bastholt,Renato G. Martins,Lisa Licitra,Michael Eschenberg,Yu Nien Sun,Todd Juan,Daniel E. Stepan,Martin Schlumberger +11 more
TL;DR: Motesanib diphosphate can induce partial responses in patients with advanced or metastatic differentiated thyroid cancer that is progressive and decrease in serum thyroglobulin concentration during treatment.
Journal ArticleDOI
Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.
Michel Marty,Pierre Pouillart,Susy Scholl,Jean Pierre Droz,Azab M,Nils Brion,Eric Pujade-Lauraine,Bernard Paule,Dominic Paes,Jacques Bons +9 more
TL;DR: It is concluded that ondansetron is more effective than metoclopramide in the control of cisplatin-induced nausea and vomiting, and that serotonin is an important mediator of this side effect.
Journal ArticleDOI
Extragonadal Germ Cell Tumors of the Mediastinum and Retroperitoneum: Results From an International Analysis
Carsten Bokemeyer,Craig R. Nichols,Jean Pierre Droz,Hans J. Schmoll,Alan Horwich,Arthur Gerl,Sophie D. Fosså,Jörg Beyer,Jörg Pont,Lothar Kanz,Lawrence H. Einhorn,Jörg T. Hartmann +11 more
TL;DR: Whereas patients with pure seminomatous EGCT histology have a long-term chance of cure of almost 90% irrespective of the primary tumor site, 45% of patients with mediastinal nonseminomas are alive at 5 years, clearly inferior compared with patients with nonseematous retroperitoneal primary tumors.